« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | Genasense |
| Generic Name: | oblimersen |
| Code Name: | G3139 |
| Company: | Genta, Inc. & Aventis |
| FDA Clinical Phase: | 3 |
Description:
Genasense is a type of antisense oligodeoxyribonucleotide. It may kill cancer cells by| Brand Name: | Aplidin |
| Generic Name: | plitidepsin |
| Code Name: | |
| Company: | PharmaMar, SA |
| FDA Clinical Phase: | 3 |
Description:
Aplidin is derived from a compound found in tunicates which shows promise in shrinking tumors.| Brand Name: | Zolinza |
| Generic Name: | vorinostat |
| Code Name: | MK0683 |
| Company: | Merck Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Zolinza (news articles), which is …
| Brand Name: | |
| Generic Name: | perifosine |
| Code Name: | KRX-0401 |
| Company: | Keryx Biopharmaceuticals / Aeterna Zentaris |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Perifosine (news articles) is a novel anti-cancer agent that is being studied for its ability to inhibit Akt, a …
| Brand Name: | Kyprolis |
| Generic Name: | carfilzomib |
| Useful Links: | News articles, forum discussions |
| Code Name: | PR-171 |
| Company: | Onyx Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
…
| Brand Name: | |
| Generic Name: | panobinostat |
| Code Name: | LBH589 |
| Company: | Novartis |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Panobinostat (news articles), which is a potent histone deacetylase (HDAC) inhibitor, selectively targets tumor cells for cell death. In Phase 1 trials, …
